Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Gene Therapy rAAV-RPE65 (LX101) in Biallelic RPE65 Mutation-associated Inherited Retinal Dystrophy: a Phase III, Multicenter, Randomized Controlled Trial (STAR)

NCT07054632 is registered in ClinicalTrials.gov with Innostellar Biotherapeutics Co.,Ltd as lead sponsor.

NCT NCT07054632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07054632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Gene Therapy rAAV-RPE65 (LX101) in Biallelic RPE65 Mutation-associated Inherited Retinal Dystrophy: a Phase III, Multicenter, Randomized Controlled Trial (STAR)
Lead sponsor
Innostellar Biotherapeutics Co.,Ltd
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 13, 2023
Completion date
August 31, 2029
Enrollment
30 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

inherited retinal dystrophy associated with rpe65 mutations